Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038618 | 0.85 | F10 (0.62) | F10F2KLK1 | |
| SCHEMBL1456174 | 0.78 | ALDH1A1 (0.57) | F10F2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1456447 | 0.78 | F10 (0.46) | F10F2NPSR1L3MBTL1KDM4E | |
| SCHEMBL4606727 | 0.78 | F10 (0.45) | F10F2KLK1 | |
| SCHEMBL4606311 | 0.78 | GABRA2 (0.49) | F10NPSR1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4063809 | 0.77 | L3MBTL1 (0.62) | NPSR1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL4604373 | 0.76 | NPSR1 (0.41) | F10F2NPSR1L3MBTL1KDM4E | |
| SCHEMBL1456889 | 0.76 | F10 (0.56) | F10F2NPSR1L3MBTL1KDM4E | |
| SCHEMBL4606036 | 0.76 | F10 (0.45) | F10F2KDM4EALDH1A1HPGD | |
| SCHEMBL4606487 | 0.75 | F10 (0.43) | F10F2KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465806-B2 | Pyrrole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-16 | — | — | US | disclosed |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| EP-1725550-A2 | PYRROLE-DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085239-A2 | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-1568698-A1 | Pyrrole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | F12, F2, F5 | F10 7/4885F2 2/4885NPSR1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.